Home
Pernix Therapeutics

Pernix Therapeutics Market Share Analysis for June 2026

Health > Biotechnology and Pharmaceuticals

Domainpernixtx.com

Year Founded1996

Employees201 - 500

Annual Revenue$100M - $200M

Pernix Therapeutics

Pernix Therapeutics (including company regionals)

pernixtx.com

See more website traffic and engagement information

Pernix Therapeutics Revenue up to June 2026 is 100M - 200M

revenue generated by Pernix Therapeutics top domains

Pernix Therapeutics top domains revenue over 3 years

Revenue for Pernix Therapeutics top domains

pernixtx.com100M - 200M

See more with Sales Intelligence

Total visits to Pernix Therapeutics's top domains

Understand Pernix Therapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Pernix Therapeutics's top domains

Analyze Pernix Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Pernix Therapeutics's top domains

See how Pernix Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Pernix Therapeutics top competitors by domain

Top similar sites in June 2026, ranked by their affinity

collegiumpharma.comCompany NameCollegium PharmaceuticalEmployees201 - 500HQUnited States, Massachusetts, StoughtonAnnual revenue$500M - $1BTotal visits11.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Pernix Therapeutics

These are the website technologies, by industry, used by Pernix Therapeutics top domains

Advertising (2)

Google Adsense

Conversion & Analytics (2)

Google Analytics

Email Services (2)

GoDaddy Email

Mobile (2)

Meta Viewport

More Technologies

3

See all

News & Signals from Pernix Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPernixtx acquired Somaxon Pharmaceuticals, Inc. for $25M on Jan 1st '14.Pernix Therapeutics (NYSE:PTX) to acquire Somaxon (SOMX); $25 million accord – PTX, CRME, DEPO, AGN, DVAX, AMRN, ALXA, PFE, JNJ.

NewsPernixtx has issues with Chapter 11 bankruptcy.The sale was consummated through Pernix’s Chapter 11 bankruptcy.

NewsPernixtx partners with Highbridge Capital Management LLC.Pernix has entered into an asset purchase agreement with debt holder Highbridge Capital Management.